UNITY Biotechnology Inc. recently announced receiving a notification from the Nasdaq Stock Market regarding non-compliance with continued listing requirements. As of June 18, 2025, the company's common stock had a closing bid price below the $1.00 per share minimum for the past 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). Additionally, as previously disclosed, the company's stockholders' equity fell below the required 10 million threshold as per Nasdaq Listing Rule 5450(b)(A)$. UNITY Biotechnology has submitted a compliance plan and an application to transfer to the Nasdaq Capital Market as it seeks to adhere to listing standards. The company has until December 15, 2025, to rectify these issues, with a potential extension available. Despite the current regulatory challenges, there is no immediate impact on the company's Nasdaq listing or stock trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。